Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of ATG-F on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical SCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient age 3-70 years old with a disease necessitating allogeneic SCT.~2. Patients must have a mismatched donor willing and capable of donating peripheral blood stem cells and/or bone marrow progenitor cells using conventional techniques, and lymphocytes if indicated (mismatched defined as 3/6-4/6 HLA matching).~3. Each patient / patient's guardian must sign written informed consent.~4. Patients must have an ECOG PS ≤ 2; Creatinine \<2.0 mg/dl; Ejection fraction \>40%; DLCO \>50% of predicted; Serum bilirubin \<3 gm/dl; elevated GPT or GOT \>3 x normal values.~Exclusion Criteria:~1. Not fulfilling any of the inclusion criteria.~2. Active life-threatening infection.~3. Overt untreated infection.~4. Known hypersensitivity to ATG.~5. HIV seropositivity, Hepatitis B or C antigen positivity with evidence of active hepatitis.~6. Pregnant or lactating women.~7. Donor contraindication (HIV seropositive confirmed by Western Blot Hepatitis B antigenemia; positive HCV antibodies with positive HCV PCR; evidence of bone marrow disease; unable to donate bone marrow or peripheral blood due to concurrent medical condition).~8. Inability to comply with study requirements.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): with ATG-F
- 2 (Type: NO_INTERVENTION): control

Based on this trial design, predict the completion outcome and termination type (if applicable).